Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1982 1
1983 3
1984 7
1985 5
1986 6
1987 12
1988 17
1989 35
1990 59
1991 23
1992 57
1993 57
1994 55
1995 71
1996 59
1997 67
1998 56
1999 43
2000 34
2001 36
2002 30
2003 29
2004 22
2005 22
2006 29
2007 20
2008 9
2009 20
2010 13
2011 14
2012 19
2013 13
2014 17
2015 21
2016 18
2017 12
2018 12
2019 8
2020 23
Text availability
Article attribute
Article type
Publication date

Search Results

1,022 results
Results by year
Filters applied: . Clear all
Page 1
Moclobemide.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 30000824 Free Books & Documents. Review.
Moclobemide is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal doses of moclobemide up to 900 mg daily produce low levels in milk. Although sev
Moclobemide is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other co
Moclobemide: therapeutic use and clinical studies.
Bonnet U. Bonnet U. CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. CNS Drug Rev. 2003. PMID: 12595913 Free PMC article. Review.
Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6, relatively few clinically important drug interactions involving moclobemide have been reported. ...There is no evidence that moclobemide would increase bod
Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6, relatively few clinically imp
Moclobemide.
Freeman H. Freeman H. Lancet. 1993 Dec 18-25;342(8886-8887):1528-32. doi: 10.1016/s0140-6736(05)80090-x. Lancet. 1993. PMID: 7902906 Review. No abstract available.
Moclobemide--placebo-controlled trials.
Silverstone T. Silverstone T. Int Clin Psychopharmacol. 1993 Jan;7(3-4):133-6. doi: 10.1097/00004850-199300730-00002. Int Clin Psychopharmacol. 1993. PMID: 8468433 Review.
In this paper, three placebo-controlled trials of moclobemide, and four three-way comparison trials of moclobemide, placebo and one of the standard tricyclic antidepressants, imipramine, clomipramine, or amitriptyline, are reviewed. ...Tolerance of moclobemide
In this paper, three placebo-controlled trials of moclobemide, and four three-way comparison trials of moclobemide, placebo an …
Bioavailability of moclobemide from two formulation tablets in healthy humans.
Główka FK, Hermann TW, Danielak D, Zabel M, Hermann J. Główka FK, et al. Pharmazie. 2019 Feb 1;74(2):97-100. doi: 10.1691/ph.2019.8819. Pharmazie. 2019. PMID: 30782258 Clinical Trial.
Carbamazepine was proposed as an internal standard and ammonia as well as Na2HPO4 as alkalizing agents for the mobile phase and the liquid-liquid extraction of moclobemide from human blood plasma, respectively. Basic pharmacokinetic parameters of moclobemide obtaine …
Carbamazepine was proposed as an internal standard and ammonia as well as Na2HPO4 as alkalizing agents for the mobile phase and the liquid-l …
[Moclobemide].
Gleiter C, Volz HP. Gleiter C, et al. Dtsch Med Wochenschr. 1995 Aug 25;120(34-35):1175-6. doi: 10.1055/s-0029-1234212. Dtsch Med Wochenschr. 1995. PMID: 7656852 Clinical Trial. German. No abstract available.
Moclobemide.
Gram LF, Isacsson G, Bergman U. Gram LF, et al. Lancet. 1994 Mar 12;343(8898):679-80. doi: 10.1016/s0140-6736(94)92680-8. Lancet. 1994. PMID: 7906848 No abstract available.
Moclobemide. An update of its pharmacological properties and therapeutic use.
Fulton B, Benfield P. Fulton B, et al. Drugs. 1996 Sep;52(3):450-74. doi: 10.2165/00003495-199652030-00013. Drugs. 1996. PMID: 8875133 Review.
Moclobemide only weakly potentiates the pressor response induced by tyramine or other indirectly acting sympathomimetics; therefore, there is no need to avoid dietary tyramine or over-the-counter decongestants with moclobemide as there is with older MAO inhibitors.
Moclobemide only weakly potentiates the pressor response induced by tyramine or other indirectly acting sympathomimetics; therefore,
Interaction studies with moclobemide.
Zimmer R, Gieschke R, Fischbach R, Gasic S. Zimmer R, et al. Acta Psychiatr Scand Suppl. 1990;360:84-6. doi: 10.1111/j.1600-0447.1990.tb05343.x. Acta Psychiatr Scand Suppl. 1990. PMID: 2248085 Review.
Drug interactions with moclobemide given to healthy subjects and depressed patients are reviewed. ...Since moclobemide is devoid of anticholinergic effects, no interaction with alcohol was anticipated. ...
Drug interactions with moclobemide given to healthy subjects and depressed patients are reviewed. ...Since moclobemide is devo …
Moclobemide safety: monitoring a newly developed product in the 1990s.
Hilton S, Jaber B, Ruch R. Hilton S, et al. J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):76S-83S. doi: 10.1097/00004714-199508001-00013. J Clin Psychopharmacol. 1995. PMID: 7593735 Review.
Moclobemide is a reversible and selective inhibitor of monoamine oxidase subtype A with a wide spectrum of antidepressant activity. ...It is of great significance that the fatal toxicity index of moclobemide is zero. A review of single-drug intoxications with moc
Moclobemide is a reversible and selective inhibitor of monoamine oxidase subtype A with a wide spectrum of antidepressant activity. .
1,022 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback